Wilson M, Wasserman M, Breton MC, Peloquin F, McDade C, Earnshaw S, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Quebec. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada.
Wasserman M, Wilson M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Previously presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases.
Earnshaw SR, Brogan AJ, Davis AE. Budget impact analysis II: applications & design issues. Presented at the 2018 ISPOR 21st Annual European Congress; November 11, 2018. Barcelona, Spain. Previously presented at the ISPOR 20th Annual International Meeting.
Mullins CD, Earnshaw SR, Brogan AJ. Budget impact analysis I: a 6-step approach. Presented at the 2018 ISPOR 21st Annual European Congress; November 11, 2018. Barcelona, Spain. Previously presented at the ISPOR 18th Annual European Congress.
Earnshaw SR. Are we ready to use constrained optimization in health outcomes research? - Editorial. Value Health. 2018 Sep;21(9):1029-30. doi: 10.1016/j.jval.2018.07.004
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1
Earnshaw S. The next level in beta-glucan research: new findings for cholesterol-lowering, gut health and more. Presented at the American Society for Nutrition Conference 2018; June 11, 2018. Boston, MA.
Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544
Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II – applications and design issues. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 20, 2018. Baltimore, MD. Previously presented at the ISPOR 20th Annual International Meeting.
Mauskopf J, Mullins CD, Earnshaw SR. Budget impact analysis I: a 6-step approach. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 20, 2018. Baltimore, MD. Previously presented at the ISPOR 18th Annual European Congress.
Wilson M, Wasserman M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.
Jarmul J, Pletcher MJ, Hassmiller Lich K, Wheeler SB, Weinberger M, Avery CL, Jonas DE, Earnshaw S, Pignone M. Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of atherosclerotic cardiovascular disease: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004171. doi: 10.1161/CIRCOUTCOMES.117.004171
Patel PA, Zyczynski TM, Beard SM, Earnshaw SR, McDade CL, Zimovetz E. A European multicountry comparison of the cost-effectiveness of iodixanol versus iohexol based on the results of the NEPHRIC clinical trial. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Farkouh RA, Earnshaw SR, Watson ME, Maroudos P. Short-term cost-effectiveness of hla*b-5701 testing prior to initiation of abacavir. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Disease Society of America 46th Annual Meeting; October 2008.
Earnshaw SR, Graham CN, Irish WD, Sato R, Schnitzler MA. Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation. J Am Soc Nephrol. 2008 Sep 1;19(9):1807-16.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Sunyecz J, Silberman C, Poston S, Earnshaw SR. Cost-effectiveness of ibandronate therapy for women with postmenopausal osteoporosis with respect to nonvertebral fracture efficacy. Poster presented at the 30th Annual Meeting of the American Society for Bone and Mineral Research; September 2008.
Farkouh RA, Earnshaw SR, Kauf TL, Watson ME, Maroudas P. Cost-effectiveness of hla*b-5701 testing prior to initiation of abacavir sulfate. Poster presented at the 17th International AIDS Conference; August 2008.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AR. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008 Jul 1;11(4):563-74.
Graham CN, Earnshaw SR, Raymond V. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis in Canada. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A98.
Bell CF, McDade CL, Black L, Earnshaw SR, Kattan MW. Considerations for modeling the cost-effectiveness of preventative prostate cancer treatments. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada.
Earnshaw SR, Candrilli SD. The nuts and bolts of measuring medication adherence: a practical approach. Poster presented at the 20th Annual Meeting of the American Managed Care Pharmacy; April 2008.
Earnshaw SR, Beard SM. Supporting reimbursement of pharmaceuticals. Presented at the INFORMS Conference on OR Practice; April 2008.